We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AbbVie earned some boasting rights this week with positive phase 3 data investigating Rinvoq (upadacitinib) as maintenance therapy for people with moderate-to-severe Crohn’s disease. Read More
Roche has run into another roadblock for its investigational dual-agent chemotherapy regimen targeting PD-L1-high locally advanced or metastatic nonsmall-cell lung cancer (NSCLC). Read More
A pooled data analysis of phase 2b and 3 data is strengthening claims that a single dose of nirsevimab can protect infants from respiratory syncytial virus (RSV) infections. Read More
An FDA-funded study suggests that different generic levothyroxine products appear equally effective, potentially laying to rest clinical concerns about how switching among them might impact blood levels of thyroid stimulating hormone (TSH). Read More
After resolving drug quality issues, Marinus Pharmaceuticals has resumed screening and recruitment for a phase 3 trial of its investigational drug ganaxolone in refractory status epilepticus (RSE). Read More
AstraZeneca’s complement-5 inhibitor Ultomiris (ravulizumab-cwvz) has shown benefit in people living with a rare degenerative neuromuscular disorder called anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). Read More
AstraZeneca’s blockbuster type 2 diabetes drug Farxiga (dapagliflozin) has already proved its efficacy in treating advanced heart failure. Now, the sodium-glucose cotransporter-2 (SGLT2) Inhibitor is showing promise as a treatment for early heart failure as well. Read More
Medicago’s investigational COVID-19 vaccine, bioengineered in the leaves of a relative of the tobacco plant, was 71 percent effective against any symptomatic cases and 78.8 percent effective against moderate-to-severe COVID-19 disease, researchers have reported. Read More
Amphista Therapeutics has entered into two lucrative partnerships that could potentially net the company more than $2 billion in sales, royalties and performance-based milestone payments. Read More